Announcements Trials

Browse Landscape

Phase

Phase 1/2 5 Phase 1 3 Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 4 Carcinoma, Transitional Cell 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Carcinoma, Renal Cell 2 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Microsatellite Instability 1 Lymphoma, Large B-Cell, Diffuse 1 Kidney Neoplasms 1 Kidney Diseases 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

Paclitaxel 23 Carboplatin 22 Capecitabine 18 Gemcitabine 16 130-nm albumin-bound paclitaxel 16 pembrolizumab 14 Cyclophosphamide 12 atezolizumab 9 Epirubicin 9 sacituzumab govitecan 8 Albumin-Bound Paclitaxel 8 eribulin 6 Vinorelbine 6 Drug Therapy 6 Doxorubicin 6 camrelizumab 4 Docetaxel 4 Cisplatin 4 Injections 3 pegfilgrastim 2 olaparib 2 famitinib 2 Filgrastim 2 Everolimus 2 veliparib 1 trilaciclib 1 toripalimab 1 taxane 1 niraparib 1 ipatasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Triple Negative Breast Neoplasms × avelumab × Clear all

NCT02926196 2025-12-12

A-Brave

Istituto Oncologico Veneto IRCCS

Phase 3 Completed

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡